

Drug Monograph

Drug Name: **Impeklo™ (clobetasol propionate) lotion**
 Drug Class: **Dermatologic Agents: Topical Corticosteroids**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Impeklo is available as clobetasol propionate 0.05% lotion in a metered-dose pump.

Manufacturer: Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505.

Indications: Impeklo is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.

Costs: \$500.10 per 68 gram pump of Impeklo. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: April Ash, PharmD.
 Date: December 31, 2020